A-431 In Vitro (3)H-thymidine Incorporation Assay (Cell Proliferation)
CAT#: ITS-1122-YF1272
Target Cell Organism: Human
Target Cell Alternative Name: A431
Target Cell Name: A-431
Assay Type: Cell Viability/Cytotoxicity and Antiproliferative Assays
Assay Overview
This assay is to provide A-431-based In Vitro (3)H-thymidine Incorporation Assay (Cell Proliferation) to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.
Target Cell Name
A-431
Target Cell Organism
Human
Target Cell Background
A-431 is a cell line exhibiting epithelial morphology that was isolated from the epidermis of an 85-year-old female patient with epidermoid carcinoma. This cell line is one of a series of cell lines established from solid tumors by D.J. Giard, et al. and can be used in cancer, toxicology, and immuno-oncology research.
Target Cell Alternative Name
A431
Related Diseases
Epidermoid Carcinoma
Research Area
Oncology
Assay Name
In Vitro (3)H-thymidine Incorporation Assay (Cell Proliferation)
Short Description
A-431-cell based In Vitro (3)H-thymidine Incorporation Assay (Cell Proliferation)
Assay Description
The 3H-thymidine incorporation assay is one such assay that can detect newly synthesized DNA in cells. Cultured cells are mixed with 3H-thymidine (radioactive) and kept for a desired incubation period. Newly replicated DNA strands can incorporate 3H-thymidine during mitosis. A scintillation counter is necessary to detect the output. Direct measurement of proliferating cells is the main advantage of this assay. However, use of harmful radioactive substances and need of special equipment are considered as main disadvantages.
Assay Type
Cell Viability/Cytotoxicity and Antiproliferative Assays
Assay Type Details
Uncontrolled proliferation is one of the main features of cancer cells. Cell-based in vitro assays are employed to determine whether test molecules possess direct cytotoxic/antiproliferative effects in cancer cells.